Shabir Madhi to Antibodies, Monoclonal
This is a "connection" page, showing publications Shabir Madhi has written about Antibodies, Monoclonal.
Connection Strength
0,873
-
A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants. J Infect Dis. 2025 Mar 17; 231(3):e478-e487.
Score: 0,224
-
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date. Paediatr Drugs. 2024 Mar; 26(2):101-112.
Score: 0,205
-
Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus. BioDrugs. 2023 May; 37(3):295-309.
Score: 0,196
-
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 07 30; 383(5):415-425.
Score: 0,163
-
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021 08 05; 184(16):4220-4236.e13.
Score: 0,043
-
Differing manifestations of respiratory syncytial virus-associated severe lower respiratory tract infections in human immunodeficiency virus type 1-infected and uninfected children. Pediatr Infect Dis J. 2001 Feb; 20(2):164-70.
Score: 0,042